Cover Image

Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Mohammed Al‐Zubaidi, Katherine Ong, Pravin Viswambaram, Haider Bangash, Glenn Boardman, Steve P. McCombie, Oliver Oey, Nicole Swarbrick, Andrew Redfern, Jeremy Ong, Richard Gauci, Ronny Low, Dickon Hayne
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	BJUI Compass
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reduced p63 expression is linked to unfavourable prognosis in muscle‐invasive urothelial carcinoma of the bladder
by: Kira Furlano, et al.
Published: (2024)

Contemporary status of diagnostic endoluminal ultrasound and optical coherence tomography in the ureter
by: Samuel Sii, et al.
Published: (2024)

Computerized tomography‐derived body composition metrics are associated with 24‐h urine lithogenic parameters
by: Reza Lahiji, et al.
Published: (2026)

The SUB ‐urothelial DUrvalumab InjEction ‐1 ( SUBDUE ‐1) trial: first‐in‐human trial in patients with bladder cancer
by: Dickon Hayne, et al.
Published: (2024)

Correction to ‘computerized tomography‐derived body composition metrics are associated with 24‐h urine lithogenic parameters’
Published: (2026)

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
by: Toshiki Kijima, et al.
Published: (2025)

Assessing EAU criteria for high‐risk upper tract urothelial carcinoma
by: Mahmoud Farzat, et al.
Published: (2025)

Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy
by: Ryo Yamashita, et al.
Published: (2024)

Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas
by: Fredrik Liedberg, et al.
Published: (2025)

Patient experience of bladder cancer: A data linkage study
by: Snehadhar Shah, et al.
Published: (2024)

Health utility value of overactive bladder in Japanese older adults
by: Takashi Yoshioka, et al.
Published: (2024)

Outcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database
by: Joshua D. Cabral, et al.
Published: (2026)

Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
by: Alison Hiong, et al.
Published: (2025)

Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker
by: Liwu Guo, et al.
Published: (2024)

Comparison of staging MRI to re‐resection for localised bladder cancer: Narrative review
by: Hugo Klempfner, et al.
Published: (2024)

Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
by: Serdar Turan, et al.
Published: (2025)

Predictors of adherence to surveillance cystoscopy for patients with non‐muscle invasive bladder cancer
by: Katherina Y. Chen, et al.
Published: (2026)

Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis
by: Yin Zhou, et al.
Published: (2024)

Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024)

Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment
by: Liam Mannion, et al.
Published: (2024)

Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
by: Shugo Yajima, et al.
Published: (2025)

Impact of pre‐stenting and bladder dranaige on intrapelvic pressure during retrograde intrarenal surgery
by: Sezgin Yeni, et al.
Published: (2025)

Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancer
by: Yu Ishizuya, et al.
Published: (2026)

Germline homologous recombination repair (gHRR) variants in bladder cancer: Preliminary evidence and clinical implications
by: Rodolfo Hurle, et al.
Published: (2025)

Lymph node dissection during cystectomy for non‐muscle‐invasive bladder cancer: A systematic review
by: Sean Lim, et al.
Published: (2026)

The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care
by: Kunal K. Sindhu, et al.
Published: (2024)

Primary retroperitoneal lymph node dissection for clinical stage II seminoma: Comparative analysis against established paradigms using the National Cancer Data Base
by: Josiah K. Low, et al.
Published: (2026)

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer
by: Jacob Hanna, et al.
Published: (2026)

Long non‐coding RNAs define favourable biology in high‐risk non‐muscle‐invasive bladder cancer
by: Rachel Weng, et al.
Published: (2025)

Understanding oncological and sexual function outcomes with gynaecological organ preserving cystectomy in women with bladder cancer; a systematic review
by: Rebecca Martin, et al.
Published: (2025)

Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study
by: Chase Peng Yun Ng, et al.
Published: (2025)

Long‐term follow‐up of intradetrusor botulinum toxin utilisation: A comparison of patients with multiple sclerosis and idiopathic overactive bladder
by: William Chui, et al.
Published: (2024)

A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion
by: John Lahoud, et al.
Published: (2024)

Real‐world use of maintenance bacillus Calmette‐Guérin therapy in patients with non‐muscle‐invasive bladder cancer in Japan: ASUKA study
by: Makito Miyake, et al.
Published: (2025)

Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
by: Amandeep Arora, et al.
Published: (2025)

Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid‐access diagnostic clinics?
by: Thomas Philip Cahill, et al.
Published: (2024)

Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer
by: Kylie Yen‐Yi Lim, et al.
Published: (2025)

Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study
by: Cameron E. Alexander, et al.
Published: (2024)

Emerging tools for the early detection of prostate cancer
by: Muhammad Haider, et al.
Published: (2025)

A population‐based analyses of the evolving management of cN1M0 prostate cancer in the PSMA‐PET era
by: Jennifer Ward, et al.
Published: (2025)